Hack Your DNA Explained: How the Behind the Markets Newsletter Subscription Is Presented to Readers
An informational overview outlining how the subscription is marketed, what materials are provided, and how publisher disclosures are framed.
CHICAGO, ILLINOIS / ACCESS Newswire / December 18, 2025 / This article is for informational purposes only and does not constitute investment advice. Investing involves risk, including potential loss of principal. Past performance does not guarantee future results. This article contains affiliate links, which are clearly marked. If you subscribe through these links, a commission may be earned at no additional cost to you.
Behind the Markets Review 2026: Dylan Jovine's CRISPR Stock Pick, Track Record, and What Investors Should Know Before Subscribing
You probably just watched a presentation. The headline mentioned something about "hacking your DNA" and a small biotech company that could supposedly deliver life-changing returns. The presenter, Dylan Jovine, talked about gene-editing breakthroughs, claimed the company is funded by Bill Gates and Google (citing "hundreds of millions" in investments), and drew comparisons to Amgen's historic gains.
And now you are here, doing exactly what a smart investor should do: researching before reaching for your wallet.
Good. That instinct will serve you well.
This guide exists to give you everything you need to make an informed decision about Behind the Markets. We will look at what the service actually provides, examine the track record claims in their proper context, explain how the subscription works, and help you figure out whether this fits your investment approach.
No breathless hype. No scare tactics. Just straight information so you can decide for yourself.
Quick Navigation
What Is Behind the Markets?
Who Is Dylan Jovine?
Understanding the CRISPR Investment Thesis
Track Record Claims in Context
What a Subscription Includes
Pricing and Refund Terms
How This Compares to Other Newsletters
Is This Right for You?
Common Questions Answered
How to Subscribe
The Bottom Line
1. What Is Behind the Markets?
Behind the Markets is an investment newsletter that provides monthly stock recommendations and market research. The company operates out of Boca Raton, Florida, and has been in business since 2018 (per public business listings; BBB maintains a profile listing the Boca Raton address).
Here is the important part to understand upfront: this is a financial publishing service, not a financial advisory firm.
According to the company's own terms of use, Behind the Markets operates under what is called the "publisher's exclusion" from investment adviser registration. In plain English, that means they publish general investment research that goes out to all subscribers equally. They do not look at your personal financial situation, your retirement timeline, your risk tolerance, or your existing portfolio and then give you customized advice.
This is how virtually every investment newsletter operates, from Motley Fool to Stansberry Research to Oxford Club. It is standard industry practice, and understanding it helps set realistic expectations about what you are buying.
You are subscribing to one analyst's research and opinions. You are not hiring someone to manage your money or tell you specifically what to do with your IRA.
Disclosure: If you register through this link, a commission may be earned at no extra cost to you.
2. Who Is Dylan Jovine?
Dylan Jovine is the founder of Behind the Markets and the voice behind the promotional presentation you likely watched.
His background, according to his own presentations, includes experience as a Wall Street market maker earlier in his career. The promotional materials describe him as having been among the youngest market makers in Wall Street history, though specific dates and firm names would require independent verification beyond company disclosures.
The presentation also includes a personal story about a health crisis that led Jovine to explore genetic medicine, which he credits with sparking his interest in biotech investing. This narrative frames his transition from general market analysis to a focus on the healthcare and biotechnology sectors.
What can be independently verified:
Behind the Markets LLC is a registered business in Florida
The company has operated since 2018
Jovine has maintained a public presence in financial media
The business maintains a BBB profile
What relies on the company's own statements:
Specific career history details
Performance statistics and track record claims
Details of past predictions
This distinction matters because it helps you calibrate how much weight to give different pieces of information. Verifiable facts carry different weight than self-reported claims, and a thoughtful investor recognizes the difference.
3. Understanding the CRISPR Investment Thesis
The promotional presentation centers on CRISPR gene-editing technology and argues that a specific small company represents a major investment opportunity. Before you can evaluate that argument, it helps to understand what is actually happening in this space.
The Science Is Real
CRISPR-Cas9 gene editing is not speculative science fiction. Jennifer Doudna and Emmanuelle Charpentier won the 2020 Nobel Prize in Chemistry for developing this technology. It allows scientists to edit DNA sequences with precision that was previously impossible.
On December 8, 2023, the FDA approved Casgevy, the first FDA-approved therapy using CRISPR/Cas9 genome editing, for sickle cell disease. Clinical trials are ongoing for various other genetic conditions. Major pharmaceutical and biotech companies have invested heavily in CRISPR-related research and partnerships.
These are facts you can verify through the FDA, NIH, and peer-reviewed scientific literature.
The Investment Case Is More Complicated
Here is where we need to separate scientific achievement from investment returns.
The promotional presentation makes sweeping claims about treating thousands of genetic diseases and creating unprecedented wealth. The marketing language includes phrases like "cure disease" and comparisons to some of the most successful biotech investments in history.
A few things to keep in mind:
Scientific promise and investment returns are different things. Genuinely transformative technologies can still produce disappointing investment outcomes. The company holding patents might fail to commercialize effectively. Competitors might develop better approaches. Clinical trials might hit unexpected obstacles. Valuations might already reflect optimistic expectations.
The patent landscape is complex. The presentation suggests one company "owns the patent" on CRISPR technology. In reality, multiple companies hold CRISPR-related patents, and there have been significant legal disputes over intellectual property in this space. The framing of single-company dominance oversimplifies a messy competitive landscape.
Biotech investing is volatile. Small-cap biotech stocks can move 20%, 30%, or more on a single piece of news. This volatility creates opportunity but also substantial risk of loss.
The presentation's thesis represents Dylan Jovine's investment opinion. He clearly believes strongly in this opportunity. His conviction does not guarantee the outcome.
A Note on Medical Claims
Some of the promotional language references specific patients being "cured" of genetic diseases. To be precise: the FDA has approved CRISPR-based treatments, and there have been significant clinical milestones. However, characterizing complex medical treatments as simple "cures" is marketing language, not medical assessment. Real-world outcomes in biotechnology are nuanced, and no treatment works identically for every patient.
Review the full research methodology and disclosures to understand how the analysis was conducted and what limitations apply.
4. Track Record Claims in Context
The promotional presentation includes specific performance claims. Let us look at what is being claimed and how to think about these numbers.
The Stated Statistics
According to the promotional materials on the company's offer page:
75.2% win rate on closed trade recommendations
43.8% average return across winners and losers
Time period: January 2018 through May 30, 2025
Publisher-reported performance is not independently audited and may not reflect typical subscriber outcomes. Subscriber results can differ materially due to entry/exit timing, fills, and portfolio sizing.
The presentation also highlights specific past recommendations with substantial gains, including positions in companies like Immunogen, ChemoCentryx, Palantir, and IONQ.
Important Context
These statistics are calculated and reported by the publisher using their own methodology. They have not been independently audited or verified by a third party. This is standard for investment newsletters, but it means you are relying on the company's own accounting.
The company's own disclosures acknowledge important limitations. Their terms state that featured results represent exceptional outcomes that "do not represent the generally expected user experience, nor do they guarantee future success."
In other words, the highlighted winners are highlighted specifically because they are exceptional. They are not presented as typical results.
Why Individual Results Vary
Even if every statistic the company reports is completely accurate, your personal experience as a subscriber will likely differ. Here is why:
Timing matters. If a stock was recommended at $10 and you join when it is already at $18, your potential gain is different from the model portfolio.
Position sizing matters. Someone who puts 2% of their portfolio in a recommendation has a different experience than someone who goes all-in.
Not everyone follows every pick. Most subscribers are selective. If you happened to skip the winners and participate in the losers, your results would look nothing like the stated averages.
Selling decisions matter. When you exit a position affects your return, and subscribers make different choices than the model portfolio.
None of this means the statistics are false. It means that aggregate historical performance and your personal future results are different things entirely.
How to Think About Track Records
Track record claims from any investment newsletter, not just this one, should be viewed as historical information about the service's recommendations, not as predictions of what you will experience. The legally required disclaimers about past performance exist for good reason: the future genuinely is uncertain.
5. What a Subscription Includes
According to the company's promotional materials, a Behind the Markets subscription provides:
Monthly Newsletter Issues
Regular issues containing investment research, new stock recommendations, and updates on existing positions. The format is typical of investment newsletters: analysis of an investment thesis, specific entry points, and guidance on when to consider selling.
Model Portfolio Access
A portfolio showing all current open positions, original recommendation prices, and current guidance. This lets subscribers see the full picture of what the service is recommending at any given time.
Alerts and Updates
Email notifications when news affects portfolio positions or when new recommendations are issued.
Bonus Reports
The current promotional offer includes several bonus reports, with the primary one being the detailed analysis of the CRISPR stock discussed in the presentation. Additional reports cover topics like biotech portfolio construction, income generation from biotech positions, and stock evaluation frameworks.
The stated values assigned to these reports ($297, $197, etc.) are the company's own pricing. Whether you find them valuable depends on whether you actually read and apply the information they contain.
6. Pricing and Refund Terms
Getting this section right is important, so let us be precise about what the company actually states.
Current Promotional Pricing
The presentation offers an introductory subscription at $49. This is described as a significant discount from the regular price.
Important: Promotional pricing can change. Always verify current terms directly before subscribing.
Refund Policy
According to the company's published refund policy page, Behind the Markets offers 30-day refundable trials, with eligibility limits that may apply. The policy notes that refundable trials may be limited to once per product every 12 months.
Before subscribing, review the current refund policy directly on the company's website to understand the exact terms that will apply to your purchase. Policies can be updated, and the terms at the time you subscribe are what govern your transaction.
Review current offers
Automatic Renewal
Like most subscription services, Behind the Markets uses automatic renewal. Your subscription will continue and your payment method will be charged unless you cancel. If you decide the service is not for you, remember to cancel before your renewal date.
How to Cancel
According to the company, you can cancel by:
Contacting customer support by phone (1-800-851-1965) or email ( [email protected])
Via your account portal where available
Support hours may vary; check the official site for current availability.
7. How This Compares to Other Newsletters
If you are considering Behind the Markets, you have probably seen promotions for other investment newsletters too. Here is some context on how the landscape looks.
The Investment Newsletter Market
Dozens of services compete for subscribers, ranging from massive operations with millions of subscribers to smaller boutique services. Most operate under the same publisher's exclusion framework and face similar challenges with track record verification.
Common Alternatives
Motley Fool runs multiple services with a longer operating history and larger subscriber base. Pricing tends to be higher, and the focus is broader across market sectors.
Stansberry Research offers numerous specialized newsletters at various price points, some costing significantly more than Behind the Markets.
Oxford Club emphasizes income strategies and dividend investing alongside growth opportunities.
Zacks uses a more quantitative, data-driven approach with stock ranking systems.
What They All Have in Common
Every investment newsletter, regardless of price or reputation:
Operates under the publisher's exclusion (general research, not personalized advice)
Faces challenges with track record verification
Cannot guarantee future results
Has both satisfied subscribers and disappointed ones
The question is not which newsletter is "best" in some absolute sense. It is which approach, focus, and analyst perspective aligns with how you want to invest.
Where Behind the Markets Fits
At $49 for the introductory offer, Behind the Markets sits at the lower end of the price spectrum, making it a relatively low-risk way to evaluate whether you find value in the service. The current focus on biotech and specifically CRISPR technology appeals to investors interested in that sector. The single-analyst approach means you get a consistent perspective rather than research by committee.
8. Is This Right for You?
Rather than telling you what to do, let me help you figure it out for yourself. Consider these questions honestly.
This Might Fit Your Approach If:
You have genuine interest in biotech and healthcare innovation. The research will make more sense and hold your attention if you actually find the science interesting. If biotech bores you, monthly issues focused on the sector will feel like a chore.
You understand what you are buying. A newsletter provides research and opinions. It does not manage your money, know your situation, or guarantee results. If you view it as one input among several in your investment process, you will likely get more value from it.
You are comfortable with volatility. Small-cap biotech stocks move dramatically. If watching a position drop 30% on clinical trial news would cause you to panic-sell or lose sleep, this sector may not match your temperament.
You practice sound position sizing. Any single stock recommendation might fail. If you understand that and size positions so that no single loss can seriously damage your portfolio, you are approaching this appropriately.
You have capital you can genuinely afford to lose. This is not the place for money you need for rent, emergencies, or near-term goals. The company's own disclosures describe biotech investing as speculative with substantial risk of loss.
You Might Want to Look Elsewhere If:
You need personalized advice. If your situation requires someone to look at your complete financial picture and give you customized guidance, you need a registered investment adviser, not a newsletter.
You have low risk tolerance. There is nothing wrong with preferring stability over speculation. But if that describes you, small-cap biotech newsletters are probably not your best fit regardless of which one you choose.
You expect guarantees. No legitimate investment service can promise specific returns. If the promotional presentation created an expectation of guaranteed profits, that expectation needs adjustment before you subscribe to anything.
You are new to investing. Learning to evaluate recommendations, manage risk, and maintain discipline during volatility takes experience. Newer investors might benefit from building foundational knowledge before adding sector-specific research services.
You believe in passive investing. If your investment philosophy holds that active stock picking cannot consistently beat index funds, a stock-picking newsletter contradicts your core belief. That philosophical mismatch will create frustration regardless of results.
Questions Worth Asking Yourself
What percentage of my portfolio would I allocate to recommendations from this service?
If a recommended position lost 50% of its value, how would I react?
Will I actually read the monthly issues and engage with the research?
Am I subscribing because I thoughtfully evaluated the service, or because the presentation got me emotionally excited?
Your honest answers matter more than anything I can tell you.
9. Common Questions Answered
Is Behind the Markets a legitimate business?
Yes. Behind the Markets LLC is a registered Florida business operating since 2018. They maintain standard business infrastructure including customer support, a member website, and published policies. Being a legitimate business does not guarantee you will profit from their recommendations, but it does mean you are dealing with a real company rather than a fly-by-night operation.
Is this a scam?
"Scam" implies fraud or intentional deception. Behind the Markets operates as a standard investment newsletter with published terms, disclosed limitations, and a refund period for new subscribers. That is not the profile of a scam. However, "not a scam" and "will definitely make me money" are entirely different questions with entirely different answers.
What is the actual stock being recommended?
The specific company name is in the detailed report provided to subscribers. The promotional presentation intentionally withholds this to incentivize subscription. This is standard practice across investment newsletters.
Can I find the stock name without subscribing?
Determined researchers sometimes identify teased stocks through presentation clues. Whether the research context and ongoing updates justify the subscription cost is a separate question.
What is the refund policy?
According to the company's published refund policy, they offer 30-day refundable trials with potential eligibility limits. Review the current policy directly before subscribing, as terms can be updated.
How do I cancel if I am not satisfied?
Contact customer support by phone (1-800-851-1965) or email ( [email protected]), or via your account portal where available. Do this before your renewal date to avoid additional charges. Support hours may vary by channel; check the official site for current availability.
Is CRISPR actually a good investment?
CRISPR is real science with legitimate medical applications. Whether specific CRISPR-related stocks are good investments depends on factors like valuation, competitive position, and your investment timeline. Promising science does not automatically equal profitable investment.
How does the track record compare to index funds?
This is an important question without a simple answer. Comparing stated newsletter returns to index fund performance requires accounting for time periods, risk levels, and whether stated returns were actually achievable by subscribers. Academic research generally shows most active stock pickers underperform indexes over time. Some outperform. Your belief about this question probably shapes whether stock-picking newsletters appeal to you at all.
10. How to Subscribe
If you have thought it through and decided this fits your approach, the subscription process is straightforward.
Step 1: Review Current Terms
Before subscribing, verify the current pricing and refund policy directly. Promotional terms change, and you want to know exactly what applies to your purchase.
Step 2: Subscribe Through the Offer Page
Affiliate link disclosure: If you subscribe through this link, a commission may be earned.
The promotional offer is available through the order page:
View the current subscription offer
This is an affiliate link. If you subscribe through it, a commission may be earned at no additional cost to you. You can also access the offer directly through the company's promotional page at go.behindthemarkets.com if you prefer.
Step 3: Access Your Account
After subscribing, you will receive login credentials for the member website where you can access newsletter issues, the model portfolio, bonus reports, and support resources.
Step 4: Read the Featured Report
Most new subscribers want to see the CRISPR stock analysis first. Beyond just the stock name, pay attention to the investment thesis and recommended approach.
Step 5: Integrate Thoughtfully
Consider how any recommendations fit within your broader portfolio. Determine appropriate position sizes based on your overall risk tolerance and allocation strategy.
11. The Bottom Line
Let me give you my honest assessment.
Behind the Markets is a real investment newsletter operated by a real company with a real track record of publishing stock recommendations since 2018. The current promotional focus on CRISPR and gene-editing technology centers on legitimate science with genuine medical applications.
That said, promotional materials use marketing language. "Cure disease," comparisons to 47,000% gains, and "once-in-a-lifetime opportunity" framing are designed to generate excitement and subscriptions. The actual experience of being a subscriber will be more mundane: monthly research, specific recommendations, some winners, some losers, and results that vary based on your timing and decisions.
The track record statistics are the company's own calculations. The highlighted gains represent exceptional results, not typical outcomes. Individual subscriber experiences vary significantly.
The biotech sector is genuinely volatile. Substantial gains are possible. Substantial losses are also possible. Anyone uncomfortable with that volatility should look elsewhere regardless of how compelling the presentation seems.
At $49 with a stated 30-day refund window, the financial risk of trying the service is relatively low. You can evaluate whether you find value in the research and cancel if you do not.
Whether this is right for you depends entirely on your situation, goals, and investment approach. This guide has given you the information. The decision is yours.
Official Links:
Company Name: Behind the Markets
Phone: 1-800-851-1965(10:00 am - 7:00 pm ET)
Email: [email protected]
Disclosures
Investment Risk Disclosure: Investing involves risk, including potential loss of principal. Past performance does not guarantee future results. Any performance figures discussed in this article are publisher-stated, calculated using their methodology, and may not reflect actual subscriber results. The stock analysis discussed represents the methodology of Behind the Markets and should not be construed as personalized investment advice. Always conduct your own research and consider consulting a qualified financial advisor before making investment decisions.
Publisher's Exclusion Notice: According to Behind the Markets' published disclosures, the service operates under the publisher's exclusion from investment adviser registration under Section 202(a)(11)(D) of the Investment Advisers Act of 1940. The service provides general financial information and opinions to all subscribers equally; it does not provide individualized investment advice tailored to any subscriber's personal financial situation.
Results Disclosure: Stock examples cited represent historical selections highlighted by Behind the Markets. According to the company's own disclosures, featured gains are described as exceptional results that "do not represent the generally expected user experience, nor do they guarantee future success." Individual investor results vary significantly based on entry timing, position sizing, holding period, and broader market conditions. Losses are possible and have occurred.
Affiliate Disclosure: This article contains clearly marked affiliate links. If you subscribe through the affiliate link, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy or editorial independence of the information presented. You may also access the offer directly through the company's website if you prefer not to use an affiliate link.
Pricing and Terms Disclosure: All subscription pricing, promotional offers, and refund terms discussed were based on publicly available information at the time of publication (December 2025) but are subject to change without notice. Always verify current pricing, refund terms, and subscription conditions directly on the official Behind the Markets website before subscribing.
Medical and Scientific Claims Disclosure: References to CRISPR technology and gene-editing treatments reflect publicly documented scientific and regulatory developments. Characterizations of medical treatments as "cures" in promotional materials represent marketing language rather than medical assessments. Actual medical outcomes vary by patient and condition. This article does not provide medical advice.
Editorial Independence: This analysis is based on publicly available information including the company's promotional materials, terms of use, refund policy, and BBB listing. The publisher of this article is not affiliated with Behind the Markets LLC beyond the disclosed affiliate relationship.
SOURCE: Behind the Markets